Idogen AB announced that it has initiated new activities in order to maximize the effect of the tolerogenic cell therapy IDO 8 before the start of the first clinical study. The company has already succeeded in establishing a patentable process for the GMP-production of individually tailored treatments. Following a successful establishment and upscaling of the manufacturing process for Idogen's cell therapy products, extensive work has been carried out with the aim of documenting and qualifying production for the planned first clinical study of IDO 8. In parallel with this, the company has conducted customary discussions with the relevant health authorities, completed the study protocol and prepared its application for the start of studies. This application is ready to be submitted as soon as the now initiated activities to optimize the production process have been completed. All in all, it can be stated that the company has succeeded in minimizing most of the negative effects on the operations that the covid-19 pandemic caused. The start of the study, which was previously expected to take place at the turn of the year 2021/22, is now planned for the beginning of the second quarter of 2022. Idogen's cell therapy is tailored for each individual patient in a GMP-certified laboratory at the company's partner Radboud University Medical Center in the Netherlands. The patentable treatment is based on a combination of dendritic cells harvested from the patient, a tolerance inducer and the substance that the body's immune system must learn to tolerate. For IDO 8, this substance consists of factor VIII, a vital drug for haemophilia A which in many patients is inactivated as a result of an unwanted immune reaction.